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Friedreich ataxia (FA) represents the most frequent type of inherited ataxia. Most patients carry homozygous
GAA expansions in the first intron of the frataxin gene on chromosome 9. Due to epigenetic alterations, frataxin
expression is significantly reduced. Frataxin is a mitochondrial protein. Its deficiency leads to mitochondrial iron
overload, defective energy supply and generation of reactive oxygen species. This review gives an overview
over clinical and genetic aspects of FA and discusses current concepts of frataxin biogenesis and function as
well as new therapeutic strategies.
Background
In 1863, Friedreich first described an inherited early
onset ataxia associated with kyphoscoliosis and fatty
degeneration of the heart in six members from two families
associated with degeneration of the dorsal columns and
dorsal roots [1]. Friedreich interpreted the disorder as a
developmental defect of the medulla oblongata. In analogy
to tabes dorsalis, he considered the spinal lesions as mainly
inflammatory. Friedreich’s work gained little attention
during his lifetime. Only 30 years after Friedreich’s original
description, Pierre Marie realized the scientific impact of
Nikolaus Friedreich’s work by discriminating FA from
dominant ataxias [2].
Epidemiology
In Western populations, the prevalence of FA varies
between 1:20 000 and 1:725 000. Epidemiological studies
gave evidence of a west to east prevalence gradient in
Europe with highest levels in the South of France, North
of Spain and Ireland and lowest levels in Scandinavia
and Russia [3]. Carrier frequencies vary between 1:55
(North Spain) and 1:336 (Russia) [3]. Human Y chromo-
some haplotype analyses point to a Franco-Cantabrian
ice age refuge origin of the FA carrying population [3].
FA is rare in sub-Saharan African populations and very
rare in the Far East.
Phenotype
Onset, progression, and death
FA is a slowly progressive disorder. Usually, the onset of
symptoms is during adolescence (mean 15.5 years, SD
8 years) with unsteadiness of gait [4]. Some individuals
first seek medical help for scoliosis. One fifth of patients
is younger than 5 years at onset [5]. Mean time to loss
of independent gait is 8 years [6]. Patients usually
become wheelchair bound after a mean disease duration
of 11–15 years (range 3 to 44 years) [5]. Disease onset
before the age of 20 and cardiac involvement are associ-
ated with faster progression of neurological symptoms
[6]. Interestingly, clinical symptoms do not progress at
the same rate. Dysarthria manifests within 10 to 15 years
and diabetes within 16 years whereas loss of propriocep-
tion takes more than 40 years to develop. Life expectancy
has improved considerably during the last years. Typical
causes of death are aspiration pneumonia, cardiac compli-
cations (60%), diabetic coma, stroke and trauma sequelae
[6, 7]. The presence of diabetes and/or dilated cardiomy-
opathy has a negative impact on survival. Overall, progno-
sis seems better in females [8].
Atypical phenotypes
With the identification of the genetic background [9],
atypical forms of FA became identifiable. It then became
evident that only 75% of patients could be diagnosed
correctly as FA cases based on the original Harding criteria
[4, 10]. Late onset FA (LOFA, onset after 25 years) or very
late onset FA (VLOFA, onset after 40 years) have a
slower progression. Non-neurological symptoms such
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as cardiomyopathy, diabetes, or skeletal deformities are
less frequent. The phenotype is often more spastic with
little or no ataxia. Therefore, FA should be considered
in the diagnostic work-up even in individuals with onset
after 60 years and absence of characteristic features.
Neurological syndrome
The core syndrome is an early onset, slowly progressive
ataxia associated with areflexia. Ataxia arises from com-
bined afferent (peripheral sensory neuropathy plus spinal
degeneration), cerebellar and sometimes also vestibular
dysfunction. In addition to ataxia of stance and gait,
patients develop appendicular and truncal ataxia. Dysarthria
is another cerebellar feature present in 70% with abnormal
pitch variation, loudness maintenance, breath support for
speech, hypernasality and consonant imprecision due
to laryngeal or velopharyngeal dysfunction [11]. Loss of
deep tendon reflexes due to degeneration of dorsal root
ganglia and peripheral neuropathy is an early and robust
feature of FA. However, preserved reflexes do not exclude
FA. Plantar responses are extensor in 70 to 90%. If spasti-
city is not masked by peripheral involvement, it should be
treated to prevent contractures and painful spasms. Mus-
cular weakness and wasting - usually more pronounced in
the lower limbs - can complicate advanced cases. Proprio-
ceptive deficits with abnormal position and vibration sense
are present in virtually all FA subjects. Nerve conduction
studies reveal signs of an axonal sensory neuropathy with
reduced or absent nerve action potentials typically first
present in the sural nerve. Cortical potentials of somato-
sensory evoked potentials are delayed or absent [3].
Square wave jerks (SWJ) represent a typical, though
not pathognomonic eye movement abnormality of FA.
They are usually horizontal and can be observed in
primary position and during smooth pursuit. Twenty
to 60% of patients show gaze evoked nystagmus
mainly on lateral gaze. Saccades are dysmetric, but of
normal velocity. Ptosis is present in about 10% of patients
[12]. Involvement of the visual system is complex. Vision is
impaired in about one fifth of patients with optic atrophy
on fundoscopy in about one third. FA may even lead to
complete blindness in late stages. This is usually
reflected by abnormal visually evoked potentials [3, 13].
Variable perimetric deficits, impaired contrast letter
acuity, reduced retinal fiber layer thickness and optic radi-
ation abnormalities have also been described [4, 13, 14].
Hearing problems are common and worsen over time
[15]. Single patients may even suffer from combined blind-
ness and deafness. Deficits mainly affect central auditory
pathways with abnormal auditory evoked brainstem poten-
tials while peripheral components are usually preserved [5].
There is electro-physiological evidence for dyssynchrony
of central auditory pathway components resulting in im-
paired discriminative hearing and verbal communication.
Autonomic dysfunction such as vasomotor abnormalities
or dyshidrosis are most prevalent in the lower limbs.
Dysphagia may complicate advanced disease requiring
percutaneous endoscopic gastrostomy (PEG) to avoid
aspiration. Micturition is only mildly affected with urgency
and detrusor hypoactivity being the most frequent symp-
toms. In a series of FA patients, there was evidence for dila-
tation of the upper urinary tract without creatinine increase
in 14% [16]. Systematic assessment of bowel function has
not been published to date.
Affective disorders affect almost all patients with
severe depression in almost 10% [17]. Dementia is not
part of the FA phenotype but systematic neuropsycho-
logical studies revealed wide-spread abnormalities of
information processing, visuoconstructive and visuospatial
capacity, verbal fluency, motor and mental reaction times,
concept formation, sustained volitional attention, working
memory as well as concrete thinking [18–21]. Cognitive
deficits have been attributed to primary prefrontal dys-
function, disruption of cerebello-prefrontal connections
or cerebro-ponto-cerebello-thalamo-cerebral circuits as
well as parieto-temporal dysfunction [18–21]. However,
the deficits do not significantly interfere with educa-
tion or social life. Many patients successfully pursue
academic careers.
Non-neurological manifestations
Cardiac involvement mainly affects young patients below
the age of 40 years [22]. It accounts for about half of
deaths in advanced stages of the disease. Echocardiography
may reveal left ventricular hypertrophy, mostly concentric
with an end-diastolic wall thickness of less than 15 mm and
usually no outflow tract obstruction. Systematic studies
report on concentric hypertrophy in 35% and eccentric
hypertrophy in 5% of patients [23]. MRI studies further
point to early development of replacement fibrosis that
develops slowly over time leading to wall thinning and
finally dilatation of the left ventricle [24]. However,
ejection fraction remains stable over many years. Only
20% of patients have an abnormal ejection fraction decreas-
ing with age [22, 23, 25]. Despite these alterations, diastolic
function usually remains relatively stable. A diastolic
pattern of pseudonormalization is usually restricted to
advanced stages [23]. Typical ECG characteristics, that
are virtually present in all patients including atypical
cases, consist of T-wave abnormalities with T-wave in-
version, ST-segment depression or elevation as well as
T-wave flattening in the left chest leads [26, 27]. ECG
may also show characteristic features of left ventricular
hypertrophy. Paroxysmal or permanent supraventricular
tachycardias like atrial fibrillation, atrial flutter or atrio-
ventricular re-entry tachycardia rarely require invasive
treatment [28]. The degree and onset of cardiac manifest-
ation is only poorly related to the severity of neurological
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symptoms [22]. Therefore, every FA patient should be
regularly followed for cardiac disease.
The prevalence for diabetes among FA patients varies
between 8 to 49% depending on the definition of diabetes
[4, 29]. Young age of onset and longer disease duration
increase the risk for diabetes. Manifestation of diabetes is
usually a late event in the course of FA (mean 15 years
after onset) [6]. The onset is often acute, sometimes with
ketoacidosis [30]. The main event in the etiology of
diabetes is the loss of pancreatic islet ß cells with con-
comitant decline of insulin secretion. The process is fur-
ther aggravated by increased insulin requirements due to
insulin resistance. Surprisingly, FA patients show elevated
body fat content despite obvious leanness [31].
Scoliosis is considered typical for FA. Its prevalence
varies between 33 and 100% depending on the individual
study [4, 5, 10, 32, 33]. Only half of cases show a pro-
gress over time. Similarly, foot deformities (pes cavus,
club foot, pes planus) may significantly interfere with
mobility in 55 to 90% of patients. Severity does not
depend on expansion size or age of onset, but disease
duration and age. Body growth may be impaired in very
early onset cases [5].
Imaging
MRI usually shows spinal atrophy. Cerebellar shrinkage
is considered less common [34–36]. Volume loss of
the medulla oblongata may be seen in advanced cases
[37]. Volumetric studies demonstrated a close relation-
ship between atrophic changes of infratentorial brain
structures and disease duration and severity [38, 39].
Recent MRI studies also gave evidence for reduced
cortical thickness especially in the premotor and sup-
plementary motor areas, disrupted fronto-cerebellar
networks as well as volume loss of extrapyramidal
structures [40–42].
Differential diagnosis
When discussing alternative etiologies in a patient
with early onset ataxia, one should keep in mind that
FA - as the most frequent inherited ataxia - represents
the most probable diagnosis in most ataxia patients. If
genetic testing for FA is negative, the following disorders
should be considered: ataxia with vitamin E deficiency,
ataxia with coenzyme Q 10 deficiency, autosomal-re-
cessive spastic ataxia Charlevoix-Saguenay (ARSACS),
spastic paraplegia (SP), ataxia with ocular apraxia type 1
and 2 (AOA1 and 2), ataxia telangiectasia (AT), ataxias
associated with POLG mutations, Aß-lipoproteinemia,
Refsum’s disease, late onset Tay-Sachs disease, cerebro-
tendinous xanthomatosis, hereditary sensory and motor
neuropathies.
Genetics
FA is an autosomal-recessively inherited disorder. Ninety-
five per cent of FA patients are homozygous for unstable
guanine-adenine-adenine (GAA) expansions in the first
intron of the frataxin gene (FXN) on the positive strand of
chromosome 9q21.11 [9]. Another 5% of FA patients are
compound heterozygotes with an expansion on one allele
and conventional mutations on the other. Symptomatic
heterozygote carriers have not been reported to date
despite significantly reduced frataxin expression [43, 44].
Less than 10 trinucleotides are considered as short, more
than 11 triplets as long normal (LN) alleles. LN > 30 are
prone to pathogenic expansions [45, 46]. Expansions asso-
ciated with FA vary from 44 to 1700 repeats with most
abnormal alleles ranging from 600 to 900 GAAs. The
length of the shorter allele is negatively correlated with
the age of onset. Longer expansions usually result in a
more severe phenotype with an earlier onset, faster pro-
gression and a higher rate of non-neurological features
[4, 47, 48]. However, the variability in age of onset
depends not only on the repeat number (50%), but also
on modifier genes, the number of stabilizing interruptions,
somatic mosaicism, and the instability of the expansion
during life. Furthermore, repeat numbers assessed in per-
ipheral blood cells do not necessarily reflect the distribu-
tion of repeat length in various tissues due to somatic
mosaicism.
Atypical phenotypes have been assigned to extremely
long or short alleles as well as point mutations. Missense,
nonsense, splicing, frame-shift deletion, del/ins nucleotide
change or large deletion impair frataxin function to a vari-
able extent [9, 49, 50]. Compound heterozygotes who carry
a missense mutation of a sequence encoding for the amino-
terminal half of frataxin usually differ from classical FA.
They show retained tendon reflexes, pronounced spasticity,
mild or absent cerebellar dysfunction and slower progres-
sion despite early onset [51]. On the other hand, the pheno-
type is not to be separated from classical FA if the missense
mutation affects the carboxy-terminal half of frataxin.
Deletions are usually associated with early onset, fast
progression and severe phenotype with a higher incidence
of non-neurological symptoms [52].
Frataxin function
Frataxin is a small molecule of 23 kDA. The mature
protein consists of amino acids 81–210 [9]. The struc-
ture is characterized by an α/β fold followed by the C-
terminal region (CTR) with a nonperiodic structure
that packs against the protein core [53]. Its impact on
cellular function and survival is impressively reflected
by early embryonic lethality in FXN knock-out mice
[54]. Frataxin localizes to the mitochondrial matrix
where it is associated with the inner mitochondrial mem-
brane. Mitochondria are crucial for normal cell functioning.
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They are not only involved in energy metabolism, but also
in the maintenance of the membrane potential, calcium
metabolism, correct protein folding, axonal transport and
synaptic transmitter homeostasis. Regarding these manifold
functions of mitochondria, potential consequences of mito-
chondrial dysfunction go beyond the classical concept of
mitochondrial respiratory chain failure with defective oxi-
dative phosphorylation (OXPHOS).
Early histological studies gave evidence for myocardial
iron deposits in FA hearts [55]. Much later, experimental
studies in yeast with a deleted FXN homolog gene yielded
mitochondrial iron accumulation, cytosolic iron depletion
and upregulation of the high-affinity iron uptake system
that is controlled by a cytosolic iron sensor and transcrip-
tion factor [56]. It was then shown that restoration of
frataxin function leads to a redistribution of iron out of
the mitochondria into the cytosol [57].
Frataxin normally activates mitochondrial iron-sulfur-
cluster (ISC) protein assembly as part of a multiprotein
complex. Frataxin deficient cells are depleted of ISC
proteins in all cellular compartments. They especially
lack mitochondrial ISC-containing subunits of respiratory
chain complexes I, II and III and aconitase activities. In
addition to its role in the assembly of ISC clusters, frataxin
is also likely to interact with complex II subunits suggesting
an imminent role in the respiratory chain. Furthermore, it
is also thought to be involved in the synthesis of heme-
containing proteins involved in a variety of cellular pro-
cesses such as oxygen metabolism and electron transfer.
Cytosolic iron responsive element binding protein 1
(IRB1), a key regulator of iron metabolism, is also an ISC
protein. When iron decreases in the cytosol, IRB1 binds to
specific sequence motifs within the mRNA for proteins
involved in iron metabolism thereby preventing degrad-
ation of mRNA of iron import proteins and inhibiting
translation of mRNA for proteins that store iron or need
iron for proper functioning. Concomitantly, the iron up-
take via the mitochondrial iron transporter into mitochon-
dria is enhanced. The lack of frataxin, however, prevents
the assembly of ISC with consecutive mitochondrial iron
overload. H2O2, that is excessively high in frataxin defi-
cient mitochondria due to the defective respiratory chain,
oxidizes ferrous iron thereby producing further toxic radi-
cals through the Fenton reaction.
Toxic reactive oxygen species (ROS) disrupt the cells’
redox balance and thereby increase oxidative stress levels.
They interfere with cell molecules and cell structures.
Among these, mtDNA is especially exposed since it is
located within the mitochondria and it is not protected
by histones as nuclear DNA. Actually, FA patients are
prone to mtDNA deletions and mutations [58]. Many
enzymes of the respiratory chain being encoded in the
mtDNA, damage to mtDNA will further increase ROS
production and oxidative stress. According to a recently
published report, frataxin could also be involved in
DNA double strand breaks [59]. However, this does not
seem to increase tumor risk in FA [60].
Under physiological conditions, mitochondrial biogenesis
is enhanced in response to increased energy demands. The
adaptiveness of this system is influenced by oxidative stress,
disturbances of the mitochondrial network, aging and a
number of gene transcription factors [61]. In FA, com-
pensation for the increased oxidative stress cannot be
adequately counteracted by up-regulation of mitochondrial
biogenesis. This was found to be most evident in early
onset cases with long expansions and low frataxin levels.
The entire mitochondrial network is organized as a
continuously changing tubular network by means of
mitochondrial fusion and fission processes. It is charac-
terized by considerable plasticity towards cellular stress.
In other neurological conditions, it has been shown that
defective mitochondrial fusion and fission is related to
death of non-proliferating neuronal cells. In FA, non-
functioning of the mitochondrial network could also
contribute to the disease process, but this has not been
studied so far. Similarly, mitochondria interact and commu-
nicate with other cell organelles such as the cytoskeleton.
Mitochondrial transport across axons and dendrites is medi-
ated by interaction with microtubules and neurofilaments.
In FA, the cytoskeleton network appears destabilized pos-
sibly due to impaired microtubule polymerization [62].
Furthermore, there is evidence from FA cell culture
and animal models, that low frataxin induces autophagy,
a process that provides the amino acid supply during
starvation by controlled degradation of intracellular pro-
teins. Autophagy can be induced by the presence of free
radicals in order to eliminate depolarized mitochondria
and other damaged cell organelles. On the other hand,
ROS can attenuate lysosomal membranes thereby dis-
turbing mechanisms of autophagy. Apoptosis represents
an alternative mechanism in case of autophagy failure.
In frataxin depleted cells, there is inconsistent experimen-
tal evidence for increased apoptosis in different tissues
[54, 63, 64]. In pancreas e.g., mitochondrial dysfunction
causes β-cell dysfunction [31]. The oxidative stress acti-
vates the mitochondrial intrinsic pathway of apoptosis
finally leading to cell death. It was also shown that
cAMP is capable of counteracting these mechanisms by
restoring the oxidative status and thereby preventing
activation of apoptosis. Regarding these data, incretin
analogs could potentially be beneficial in FA [65].
Frataxin biogenesis
In FA patients, frataxin is reduced to 5 to 35% of the
levels of healthy individuals while levels in asymptom-
atic heterozygotes are reduced by 50% [66]. Expression
levels are correlated to the repeat length and disease
severity.
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Mature mRNA from the primary transcript not being
impaired, abnormal splicing was not likely to account for
reduced expression [67]. It has been speculated whether
expression silencing could be related to formation of non-
B DNA structures (triplexes or sticky DNA), of a persist-
ent DNA x RNA hybrid, or of heterochromatin formation
[68]. Actually, animal and human FA cell models point to
abnormal formation of heterochromatin as indicated by
histone hypoacetylation (mainly histones 3 and 4) and
trimethylation of histone 3 lysine 9 of expanded FA alleles
[69–72]. This expression repressive chromatin spreads to
the FXN promotor thereby inducing epigenetic promotor
silencing. The latter is rendered transcriptionally non-
permissive causing defective transcriptional initiation
[73–75]. The repeat length directly influences the extent
of promotor silencing and the deficiency of transcriptional
initiation [76]. There is also evidence for moderately
impaired transcriptional elongation [77]. The identifica-
tion of these epigenetic alterations opened new thera-
peutic approaches using histone deacetylase inhibitors
(HDACi) to restore frataxin expression (see below).
Concerning non-repeat mutations, it was recently shown
that mutations affecting the hydrophobic core of frataxin
cause altered stability while surface residue mutations
impact on interactions with iron sulfur cluster assembly
and heme biosynthetic proteins [78].
Pathology
Nervous system
Degenerative changes usually start in dorsal root ganglia.
There is evidence for reduction of large neurons and loss
of large myelinated fibers in the central axons and dorsal
root nerves. Interestingly, small unmyelinated fibers seem
unattenuated [79]. Axonopathy resulting from defective
axonal and mitochondrial transport along the axon would
lead to a retrograde dying-back mechanism spreading to
the CNS. Actually, dorsal columns, cuneate and gracile
nuclei, dorsal nuclei of Clarke, spinocerebellar and corti-
cospinal tracts as well as the efferent cerebellar system
become affected over time with degeneration of dentate
nuclei and superior cerebellar peduncles [79].
Heart
Histological changes encompass cellular hypertrophy,
diffuse fibrosis and focal myocardial fibrosis as well as
inflammatory infiltration, scarring and accumulation of
iron in the left ventricle [79, 80].
Therapy
Regarding the limited regeneration potential of the
nervous system, improving clinical symptoms represents a
challenge in degenerative disorders. Slowing progression
rates is therefore a more realistic approach, but it is diffi-
cult to assess. Despite the availability of evaluated clinical
scales such as the International Ataxia Rating Scale
(ICARS), the FA Rating Scale (FARS) or the Scale for the
Assessment and Rating of Ataxia (SARA), and the use of
biomarkers, the verification of any positive effects on
neurological dysfunction remains challenging [81]. It is
therefore not surprising that clinical trials have also
focused on cardiac endpoints. However, neurological
deficits are more relevant to patients’ quality of life while
most patients never experience cardiac symptoms.
Restoring reduced frataxin levels appears an appropriate
approach for slowing down or stopping FA. Actually,
experimental data principally demonstrate effectiveness of
gene replacement strategies but problems with targeted
delivery, genotoxicity and controlled expression remain
largely unsolved. Further therapeutic concepts comprise
enhancers of energy metabolism, antioxidants, increasing
frataxin, iron chelators, erythropoietin, immune modula-
tors as well as HDACi and iRNAs.
Enhancers of energy metabolism
L-carnitine and creatine, both enhancers of cellular
energy transduction, failed to significantly improve
mitochondrial ATP production, clinical symptoms and
cardiac hypertrophy in a placebo-controlled triple-phase
crossover trial over 4 months [82]. Thiamine (vitamin B1),
a cofactor of several enzymes involved in energy metabol-
ism, was found to be reduced in the CSF of FA patients. In
an open-label trial over 80 to 930 days, neurological and
cardiac symptoms significantly improved under intravenous
thiamine while the effect on frataxin mRNA blood levels
was less consistent [83].
Antioxidants
The antioxidant coenzyme Q10 (CoQ) can protect mole-
cules from oxidation and thereby counteract the increased
oxidative stress in FA. Due to its hydrophobic properties,
CoQ is rather poorly resorbed from the gut. However, oral
CoQ passes through the blood-brain-barrier. In FA,
several clinical trials failed to demonstrate a significant
improvement of neurological manifestations under CoQ
in combination with vitamin E. Nevertheless, there was
some evidence for a stabilizing effect on progression of
neurological symptoms [84]. Similarly, some biomarkers
such a magnetic resonance spectroscopy (MRS) of heart
and skeletal muscle or echocardiography yielded some
positive effects [84–86]. The structural CoQ analogue
idebenone combines improved bioavailability with the
antioxidant properties of CoQ. It also enters the brain
with significant levels in brain mitochondria [87]. However,
CSF levels after low oral doses are close to detection limit
[88]. This is in accordance to several trials that failed to
demonstrate consistent effects of low doses of idebenone
on neurological symptoms while cardiac outcome measures
appeared more ambiguous [89–98]. Since idebenone is
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well-tolerated in FA, several trials using between 10
and 75 mg/kg/d followed [99–103]. Both multi-center
phase III randomized placebo controlled trials, the
North American IONIA and the European MICONOS
with their open-label extension studies did not meet
their primary neurological endpoints [102, 104]. Two
doses of α-tocopheryl quinone (A0001), another antioxi-
dant, were assessed for their ability to improve in vitro
measures, glucose metabolism, and neurological func-
tion in a double-blind, randomized, placebo-controlled
trial over 4 weeks. There was a dose-dependent im-
provement of neurological symptoms whereas glucose
metabolism remained unaltered [105].
Increasing frataxin
In cellular and animal models of FA, the natural polyphenol
resveratrol was found to increase frataxin expression and to
act as an antioxidant. The effect of low and high doses of
resveratrol were studied in an open-label, non-randomized
trial. While frataxin levels in peripheral blood cells, patient-
reported outcome measures and cardiac parameters did
not change over 12 weeks, neurological symptoms were
found to improve in the high dose group [106].
Functional mitochondrial maturation of the frataxin
precursor comprises degradation by the ubiquitin/prote-
asome system. There is also experimental evidence that
frataxin levels may be increased by small molecules, the
so-called ubiquitin-competing molecules (UCM), that
bind to the frataxin ubiquitination site thereby blocking
its ubiquitination and degradation, promoting frataxin
accumulation and aconitase rescue in human FA cells.
So, UCMs could offer novel therapeutic approaches to
FA in the future [107]. Zinc finger nuclease-mediated ex-
cision of the expanded GAA repeats represents another
approach to increase frataxin expression [108].
Direct delivery of human frataxin to mitochondria could
also be effective in FA. Actually, a fusion protein of frataxin
and transactivator of transcription (TAT) protein transduc-
tion domain was shown to be able to penetrate cells, to
bind iron, to reduce caspase-3 activation in an exogenous
iron-oxidant stress model and to increase life span in an
animal model of FA. TAT-frataxin fusion proteins therefore
seem good candidates for a protein replacement therapy in
FA [109].
Iron chelators
Desferoxamine, a widely used iron chelator for iron over-
load conditions does not cross the blood brain barrier.
Due to its high-affinity to iron, it can easily cause extra-
cellular iron depletion with the risk of increasing the dis-
equilibrated iron metabolism in FA. In contrast, the orally
administered lipid-soluble iron-chelator Deferiprone has a
low-affinity to iron. It is capable of penetrating mem-
branes and the blood-brain-barrier. It was also shown to
transfer iron from iron-overloaded cells to extracellular
apotransferrin and pre-erythroid cells for heme synthesis
[110]. In cell culture studies, deferiprone at low concentra-
tions was found to induce frataxin biosynthesis, whereas it
downregulated frataxin production at high concentrations.
Another disadvantage is the risk for agranulocytosis.
Basically, clinical trials confirmed these observations
with worsening of symptoms of higher doses. Positive
effects especially on cardiac symptoms were induced by
low doses deferiprone [108, 110–112].
Erythropoietin (EPO)
Experimental studies suggested a potential benefit of EPO.
In several cell models, EPO elicited a dose-dependent in-
crease of frataxin [113]. In human disease, randomized
controlled trials failed to establish significant changes of
frataxin expression or clinical parameters [114, 115].
Immune modulators
Interferon (IFN)γ-1b is an endogenous immune modulator
that was shown to increase frataxin mRNA and protein
levels in cell and animal FA models. A small phase I,
open-label trial suggested positive effects on neurological
symptoms in juvenile FA despite unaltered frataxin levels
[116]. Phase II and III trials currently aim to define opti-
mal doses in adults and children with FA [117].
HDACi
The aim of HDACi is boosting frataxin expression by
targeting FXN gene silencing. The human genome harbors
18 histone-deacetylase enzymes. They are divided into
four groups, that are either zinc-dependent (class I, II and
IV) or NAD+-dependent (class III, syn. sirtuins). Pimelic
2-aminobenzamide HDAC-inhibitors were found to most
effectively induce frataxin expression by increasing acetyl-
ation at lysine residues in histones 3 and 4 within intron 1
in human cell and animal FA models [72, 118]. These
HDACi did not exert significant effects on normal alleles.
They were found to target HDAC class I enzymes with a
relative preference to HDAC3 over other class I HDACs
and exhibit long-lasting effects due to slow dissociation
characteristics [118]. Long term application of the amino-
benzamide HDACi compound 109/RG2833 restored FXN
promotor structure, increased neuronal frataxin mRNA
and protein levels as well as histone acetylation of specific
histone residues at the FXN locus. The substance also
improved coordination and was not associated with
toxicity [119–121]. Meanwhile, a phase Ib clinical trial
with compound 109/RG2833 has been successfully
completed [122]. Compound 109/RG2833 is currently
further engineered to improve its brain distribution and
metabolic stability [123]. Nicotinamide (vitamin B3)
represents another HDACi that was found effective in
preclinical FA models. An open-label, dose-escalation
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study demonstrated that higher doses boosted frataxin
expression and attenuated abnormal heterochromatin,
but failed to establish any clinical benefit. Nicotinamide
was well-tolerated by FA patients [124].
Repeat-targeted nucleic acids
In patient-derived cells, frataxin expression was en-
hanced by introducing anti-GAA duplex RNAs or
single-stranded locked nucleic acids thereby counter-
acting transcriptional repression caused by an R-loop
that forms between the expanded repeat RNA and
complementary genomic DNA [125].
Treatment of associated features
Therapy of cardiac symptoms should follow conventional
standards [126]. For diabetes, therapeutic strategies com-
prise lifestyle optimization, sulfonylurea, glucagon-like
peptide 1 analogues, dipeptidyl peptidase IV inhibitors as
well as exogenous insulin. Metformin and thiazolidine-
dione impair complex I and may therefore not be suitable
for the use in FA. Moreover, the latter have also been asso-
ciated with congestive cardiomyopathy [34].
Conclusion
Taken together, there is a variety of abnormal cellular
processes in FA. It is currently not really understood
why frataxin deficiency especially targets the nervous
system. Impaired functions and pathways differ between
various cell types and do not necessarily follow the same
temporal pattern. Further studies addressing the specific
susceptibility of various tissues to FNX deficiency will
have to be performed in the future. Increased oxidative
stress represents a target to therapeutic intervention. In
this context, it is also of importance to discriminate
between defective antioxidant protective mechanisms
and abnormal ROS generation resulting from respiratory
chain defects [127].
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onset Friedreich ataxia; MRI: Magnetic resonance imaging; mRNA: Messenger
RNA; MRS: Magnetic resonance spectroscopy; mtDNA: Mitochondrial DNA;
NAD+: Nicotinamide adenine dinucleotide; OXPHOS: oxidative phosphorylation;
PEG: Percutaneous endoscopic gastrostomy; POLG: Polymerase γ; RNA: Ribonucleic
acid; ROS: Reactive oxygen species; SARA: Scale for the Assessment and Rating of
Ataxia; SD: Standard deviation; SP: Spastic paraplegia; SWJ: Square wave jerks;
TAT: Transactivator of transcription; UCM: Ubiquitin-competing molecule;
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